Clinical Trials Logo

Congenital Hyperinsulinism clinical trials

View clinical trials related to Congenital Hyperinsulinism.

Filter by:

NCT ID: NCT00987168 Completed - Clinical trials for Congenital Hyperinsulinism

Sandostatine® LP and Hyperinsulinism

Start date: May 2009
Phase: Phase 2
Study type: Interventional

To replace Sandostatine® in three daily subcutaneous injections by a single intramuscular injection of Sandostatine® LP per month in patients with a diffuse form of hyperinsulinism.

NCT ID: NCT00897676 Completed - Clinical trials for Congenital Hyperinsulinism

Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity

Start date: May 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to examine the effects of exendin-(9-39) on fasting blood glucose and protein induced hypoglycemia on subjects with Congenital Hyperinsulinism. Funding Source - FDA Office of Orphan Products Development (OODP).

NCT ID: NCT00835328 Terminated - Clinical trials for Congenital Hyperinsulinism

Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia

Start date: August 26, 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The primary aim of this study is to evaluate the effect of Exendin (9-39) on glucose requirements to maintain euglycemia in pediatric patients with congenital hyperinsulinism (CHI) who have failed medical therapy. The secondary aims are to determine the therapeutic plasma levels, plasma half-life and pharmacokinetics of Exendin (9-39) during a 9-hour intravenous infusion.

NCT ID: NCT00674440 Completed - Hyperinsulinism Clinical Trials

Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism

Start date: December 2004
Phase: Phase 2
Study type: Interventional

Children with congenital hyperinsulinism (CHI) have low blood sugar, and some of these children may require surgery. In this study, researchers affiliated with the University of Pennsylvania will test how well a radioactive drug (called F-DOPA) can detect a form of hyperinsulinism that may be cured by surgery. Eligible participants in this study will have positron emission tomography (PET) scans with F-DOPA prior to surgery.

NCT ID: NCT00571324 Completed - Clinical trials for Congenital Hyperinsulinism

Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism

Start date: August 2007
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine if Exendin-(9-39), an antagonist of the glucagon-like peptide-1 (GLP-1) receptor with effects on the pancreatic beta cell, increases fasting blood glucose levels in subjects with congenital hyperinsulinism.